Description

bluebird bio, Inc. is a pioneering biotechnology firm dedicated to the research, development, and commercialization of groundbreaking gene therapies. Their core mission is to address severe genetic disorders with potentially life-changing treatments. The company's robust pipeline of therapeutic candidates targets specific severe conditions. These include betibeglogene autotemcel (beti-cel) designed for transfusion-dependent ß-thalassemia, lovotibeglogene autotemcel (lovo-cel) aimed at sickle cell disease (SCD), and elivaldogene autotemcel, which is being developed to treat cerebral adrenoleukodystrophy (CALD). Their active clinical development initiatives are assessing the safety and effectiveness of these therapies. For instance, lovo-cel's potential for SCD patients is being evaluated across studies HGB-205, HGB-206, and HGB-210. Similarly, beti-cel's performance in ß-thalassemia treatment is under investigation in the HGB-204, HGB-205, HGB-207, and HGB-212 trials. Further strengthening its capabilities, bluebird bio maintains strategic collaborations and licensing arrangements with companies such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, initially established as Genetix Pharmaceuticals, Inc., adopted its current name, bluebird bio, Inc., in September 2010. Founded in 1992, its corporate headquarters are situated in Cambridge, Massachusetts.